All the Latest From Neuropore
Check back for the latest media updates from Neuropore.
News
Neuropore Therapies Receives a Grant from The ALS Association February 17, 2020Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program.
Neuropore Therapies Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34 January 13, 2020Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34. NPT520-34 is a small molecule being developed for Parkinson’s disease and amyotrophic lateral sclerosis.
Neuropore Therapies Appoints Dr. Joseph S. McCracken to Board of Directors October 29, 2019Neuropore Therapies, Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease, announced today the appointment of Joseph S. McCracken, DVM, MS to its board of directors.
Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosis August 14, 2019Neuropore Therapies, Inc. announced announced today that it has received orphan drug designation for NPT520-34 for the treatment of amyotrophic lateral sclerosis or ALS. The orphan drug designation will facilitate the development of NPT520-34 in the treatment of this debilitating medical condition for which limited treatments are available.
Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence August 5, 2019Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence. The molecular targets of interest are implicated in dysfunctions in proteostasis and can therefore be modulated to restore normal cellular protein clearance mechanisms. The collaboration aims to discover small molecule therapeutics for multiple targets.
UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration May 28, 2019Neuropore Therapies, Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinson’s disease patients with UCB0599 in the United States of America. UCB0599, an alpha-synuclein misfolding inhibitor, is a therapeutic candidate arising from the Neuropore-UCB collaboration. Neuropore will receive a $5 million (USD) award as a result of achieving this milestone.
Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis May 8, 2019Neuropore Therapies, Inc. announced today that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetics of NPT520-34.
Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.
Neuropore Therapies Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research January 30, 2017Neuropore Therapies, Inc. has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.
Neuropore Therapies Announces Appointment of Dr. Errol De Souza as President and Chief Executive Officer January 23, 2017Neuropore Therapies, Inc. announced today that Errol De Souza, Ph.D. has been appointed President and Chief Executive Officer effective immediately.
See All NewsEvents
Neuropore Therapies (NPT™) will be present at BIO Asia International Conference 2020 March 10-11, 2020Tokyo, Japan
See All Events